Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 12,523 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Ventricular Dysfunction, Left
Interventions: Revivent TC; Device
Lead sponsor: BioVentrix; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 20 more

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 36
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 23 more

Conditions: Femur Neck Fracture
Interventions: Teriparatide, Placebo, Calcium supplementation, Vitamin D supplementation; Drug · Dietary Supplement
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 24
States / cities: Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 21 more

Conditions: DERMATOMYOSITIS OR POLYMYOSITIS
Interventions: MEDI-545, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Scottsdale, Arizona • Stanford, California • Whittier, California + 11 more

Conditions: Hyperlipidemia
Interventions: ETC-1002, Atorvastatin, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Anaheim, California • Los Angeles, California • Northridge, California + 16 more

Conditions: HIV Infections, Cancer, Pain
Interventions: Ziconotide; Drug
Lead sponsor: Neurex; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 44
States / cities: Huntsville, Alabama • Mobile, Alabama • Northport, Alabama + 38 more

Conditions: Asymptomatic HIV, HIV Infections
Interventions: Index Recruiter, Friendship Network Member; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years to 24 Years · Female only
Enrollment: 535 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miami, Florida • Chicago, Illinois • The Bronx, New York

Conditions: Alcoholic Hepatitis
Interventions: DUR-928 30 mg, DUR-928 90 mg, DUR-928 150 mg; Drug
Lead sponsor: Durect; Industry
Eligibility: 21 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: San Diego, California • Miami, Florida • Atlanta, Georgia + 4 more

Conditions: Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions: bleomycin sulfate, doxorubicin hydrochloride, liposomal vincristine sulfate, vinorelbine tartrate, cyclophosphamide, etoposide phosphate, prednisone, filgrastim, ifosfamide; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 156
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 121 more

Conditions: Breast Cancer Metastatic
Interventions: Paclitaxel, Pelareorep, Avelumab; Drug · Biological
Lead sponsor: Oncolytics Biotech; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Miami, Florida • Urbana, Illinois • Indianapolis, Indiana + 13 more

Conditions: Hepatitis B
Interventions: Adefovir Dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Rucaparib, Placebo; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 22
States / cities: Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more

Conditions: Sarcoma
Interventions: sorafenib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 184
States / cities: Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 119 more

Conditions: Cervical Cancer
Interventions: Zalifrelimab, Balstilimab; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 13
States / cities: Goodyear, Arizona • Duarte, California • Miami, Florida + 10 more

Conditions: Atopic Dermatitis
Interventions: RVT-501 0.5% topical ointment; Drug
Lead sponsor: Dermavant Sciences GmbH; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 12
States / cities: Anniston, Alabama • Irvine, California • Jacksonville, Florida + 7 more

Conditions: Hypercholesterolemia
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections, Pregnancy
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 5
States / cities: Miami, Florida • Detroit, Michigan • Memphis, Tennessee

Conditions: COVID-19
Interventions: JINZHEN Granules for Oral Solution, Placebo; Drug
Lead sponsor: Lianyungang Kanion Group, Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Canyon Country, California • Hialeah Gardens, Florida • Miami, Florida + 7 more

Conditions: Migraine Disorders
Interventions: sumatriptan succinate/naproxen sodium, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 52
States / cities: Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more

Conditions: Postpartum Depression
Interventions: Placebo, SAGE-547 90 μg/kg/h; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 32
States / cities: Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more

Conditions: Obesity
Interventions: Placement of Snowshoe Suture Anchors, Moderate Intensity Diet & Exercise Program; Device · Behavioral
Lead sponsor: USGI Medical; Industry
Eligibility: 22 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 1 more

Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Primary Graft Non-Function, Surgically-Induced Liver Failure
Interventions: ELAD; Biological
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 14 more

Conditions: Acute Ischemic Stroke
Interventions: Argatroban, Eptifibatide, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 61
States / cities: Birmingham, Alabama • Fullerton, California • La Jolla, California + 47 more

Conditions: Fuchs' Endothelial Dystrophy, Corneal Edema
Interventions: Endothelial keratoplasty, PRGF; Procedure · Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Indianapolis, Indiana

Search by objective public record fields.

BioVentrix Revivent TC™ System Clinical Study

A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients

Effect of Teriparatide on Hip Fracture Healing

A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

ID and Testing Via Friendship Networks

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas

A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

JINZHEN for Treatment of Mild to Moderate COVID-19

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

A Feasibility Study for the Treatment of Primary Obesity

Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)

Multi-arm Optimization of Stroke Thrombolysis

Plasma Rich in Growth Factors in Corneal Endothelial Transplantation